

Treatment of MF-associated Anemia

References

1. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: The Mayo Clinic experience. *Mayo Clin Proc.* 2012;87:25–33.
2. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Myeloproliferative neoplasms. Version 1.2020—May 21, 2020.
3. Cervantes F, Isola IM, Alvarez-Larran A, et al. Danazol therapy for the anemia of myelofibrosis: Assessment of efficacy with current criteria of response and long-term results. *Ann Hematol.* 2015;94:1791–1796.
4. Birgegard G. Does anything work for anaemia in myelofibrosis? *Best Pract Res Clin Haematol.* 2014;27:175–185.
5. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: Results in 20 patients and review of the literature. *Br J Haematol.* 2004;127:399–403.
6. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. *Br J Haematol.* 2006;134:184–186.
7. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. *Eur J Haematol.* 2009;83:154–155.
8. Cervantes F, Alvarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term results in 30 patients. *Br J Haematol.* 2005;129:771–775.
9. Hernandez-Boluda JC, Martinez-Trillos A, Garcia-Gutierrez V, et al. Long-term results of prednisone treatment for the anemia of myelofibrosis. *Leuk Lymphoma.* 2016;57:120–124.
10. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial. *J Clin Oncol.* 2004;22:424–431.
11. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. *Blood.* 2003;101:2534–2541.
12. Abgrall JF, Guibaud I, Bastie JN, et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: A prospective, randomized, double-blind, multicenter study. *Haematologica.* 2006;91:1027–1032.

13. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial. *J Clin Oncol*. 2013;31:1285–1292.
14. Mesa RA, Kiladjan JJ, Catalano JV, et al. Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF). Presented at the 2017 ASCO Annual Meeting, June 6, 2017; Chicago. Abstract #25.
15. Harrison C, Vannucchi A, Platzbecker U, et al. Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). Presented at the 2017 ASCO Annual Meeting, June 6, 2017; Chicago. Abstract #7001.
16. Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. *Blood*. 2017;129:1823-1830.
17. Kovac S, Böser P, Cui Y, et al. Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels. *Haematologica*. 2016;101:e173-e176.
18. Gerds AT, Vannucchi AM, Passamonti F, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. *Blood*. 2019;134 (Supplement_1):557.